StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Clovis Oncology (CLVS) PT Raised to $33 at H.C. Wainwright
May 18, 2020 7:47 AM
H.C. Wainwright analyst Edward Wright raised the price target on Clovis Oncology (NASDAQ: CLVS) to $33.00 (from $29.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Clovis Oncology (CLVS) Prices 11.09M Share Common Offering at $8.05/Sh
May 19, 2020 5:41 AM
Clovis Oncology (CLVS) Received FDA Approval for Rubraca as Monotherapy Treatment for Patients with BRCA1/2-Mutant, mCRPC
May 15, 2020 2:31 PM
Rubraca® (Rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Recept
May 15, 2020 2:30 PM
